Literature DB >> 19578608

Seroprevalence of Helicobacter pylori in patients with colon adenomas in a Brazilian university hospital.

Abadia Gilda Buso1, Haroldo Luis Oliva Gomes Rocha, Débora Miranda Diogo, Priscila Miranda Diogo, Augusto Diogo-Filho.   

Abstract

CONTEXT: The association between Helicobacter pylori infection and colon neoplasia has been the subject of recent investigations which have produced controversial results.
OBJECTIVE: To evaluate the prevalence of H. pylori infection in patients with colonic adenomas and also in patients whose colonoscopy exams were normal.
METHODS: After colonoscopy, the individuals were distributed into two groups: patients with colon adenomas (cases) and patients whose colons were normal (controls). The groups were similar regarding age and gender. The individuals of both groups were subjected to a dosage of IgG antibody against H. pylori. The dosage was applied according to the solid phase, chemiluminescent immunometric assay. The chi-square test was used to analyze the data.
RESULTS: There were 30 men and 64 women in each group (94 cases and 94 controls). The mean age of the cases was 59.79 +/- 12.25 years and that of the controls was 58.98 +/- 11.55 years. The H. pylori serology was positive for 66 (70.21%) of the cases and for 51 (54.25%) of the controls. There was a significant difference (P = 0.024). The odds ratio was 1.98 (CI 95%, 0.82-3.15). The prevalence of H. pylori in cases and controls according to gender, histological type and location of the colon lesions showed a significant difference only among women (P = 0.03), among patients with tubular adenomas (P = 0.03), and in those with distal adenomas (P = 0.038).
CONCLUSION: There is a positive association between H. pylori infection and colonic adenomas. This association is more evident in women, especially for tubular adenomas and distal colonic location.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19578608     DOI: 10.1590/s0004-28032009000200004

Source DB:  PubMed          Journal:  Arq Gastroenterol        ISSN: 0004-2803


  8 in total

Review 1.  Role of bacteria in oncogenesis.

Authors:  Alicia H Chang; Julie Parsonnet
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

2.  Combination of Triple Therapy and Chronic PPI Use May Decrease Risk of Colonic Adenomatous Polyps in Helicobacter pylori Infection.

Authors:  Rina Zuniga; Josef Bautista; Katherine Sapra; Keith Westerfield; Susan Williams; Alexander M Sy
Journal:  Gastroenterol Res Pract       Date:  2015-05-12       Impact factor: 2.260

3.  Helicobacter pylori and gastrointestinal symptoms in diagnostics and adjuvant chemotherapy of colorectal cancer.

Authors:  Leena-Maija Soveri; Pia Osterlund; Tarja Ruotsalainen; Tuija Poussa; Hilpi Rautelin; Petri Bono
Journal:  Oncol Lett       Date:  2013-11-29       Impact factor: 2.967

4.  Association of Helicobacter pylori Infection With Colon Cancer and Adenomatous Polyps.

Authors:  Fatemeh Teimoorian; Mohammad Ranaei; Karimollah Hajian Tilaki; Javad Shokri Shirvani; Zeinab Vosough
Journal:  Iran J Pathol       Date:  2018-09-12

5.  Helicobacter pylori and colorectal cancer-A bacterium going abroad?

Authors:  Julia Butt; Meira Epplein
Journal:  PLoS Pathog       Date:  2019-08-08       Impact factor: 6.823

6.  Risk for Colorectal Neoplasia in Patients With Helicobacter pylori Infection: A Systematic Review and Meta-analysis.

Authors:  Da Sol Choi; Seung In Seo; Woon Geon Shin; Chan Hyuk Park
Journal:  Clin Transl Gastroenterol       Date:  2020-02       Impact factor: 4.396

7.  H. pylori Infection and Colorectal Cancers by Anatomical Locations.

Authors:  Dao Viet Hang; Dinh Thi Minh; Tran Hieu Hoc; Le Hong Phuoc; Tran Que Son; Ngoan Tran Le
Journal:  Asian Pac J Cancer Prev       Date:  2020-08-01

8.  Association between Helicobacter pylori infection and the risk of colorectal cancer: A systematic review and meta-analysis.

Authors:  Yuling Zuo; Zhao Jing; Mingjiang Bie; Chunyan Xu; Xinyu Hao; Baoning Wang
Journal:  Medicine (Baltimore)       Date:  2020-09-11       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.